# A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

> **NCT05363722** · PHASE1 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** IBI310（0.5mg/kg）
- **DRUG:** IBI310（0.3mg/kg）
- **DRUG:** sintilimab
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT05363722
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05
- **Primary completion:** 2023-04
- **Final completion:** 2024-04
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363722, "A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05363722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*